Title Page 1

- 2 **Title:** Conduction system pacing is superior to reduce the new-onset atrial fibrillation
- 3 risk compared with right ventricular pacing: insights from pooled clinical evidence
- 5 Running title: The new-onset AF on CSP
- **Authors:** Feng Li, MD^{1#}, You Zhang, MD^{1#}, Si-Liang Peng, MD^{1#}, Meng-Chao Jin, 7
- MD¹, Chi Geng, MD¹, Venkatesh Ravi, MD², Parikshit S. Sharma, MD, MPH^{2*}, 8
- Pugazhendhi Vijayaraman, MD^{3*}, Hui Li, MD^{1*} 9

11 **Author Affiliations:**

4

6

10

18

20

- 12 1. Department of Cardiology, The Second Affiliated Hospital of Soochow University,
- 13 Suzhou, Jiangsu, 215004, China.
- 14 2. Dept of Internal medicine, Division of Cardiology, Rush University Medical Center
- Chicago, IL 15
- 3. Geisinger Heart Institute, Geisinger Wyoming Valley Medical Center, MC 36-10, 16
- 1000 E Mountain Blvd, WilkesBarre, PA 18711; 17
- 19 #The first three authors contributed equally to this work.

21 *Correspondence author:

- 22 Dr. Hui Li, Department of Cardiology, The Second Affiliated Hospital of Soochow
- 23 University, Suzhou, Jiangsu, 215004, China. Tel: 051267784077;

^{24 9911263@163.}com.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- Dr. Pugazhendhi Vijayaraman, Geisinger Heart Institute, Geisinger Wyoming Valley 1
- 2 Medical Center, MC 36-10, 1000 E Mountain Blvd, WilkesBarre, PA 18711. Email:
- 3 pvijayaraman1@geisinger.edu.
- Dr. Parikshit S. Sharma, Dept of Internal medicine, Division of Cardiology, Rush 4
- 5 University Medical Center, Chicago, IL. Tel: 201-931-6499. Email:
- 6 Parikshit S Sharma@rush.edu.

Conflict of interests 8

- 9 The authors declare that there is no conflict of interests regarding the publication of
- 10 this paper.

7

11

16

19

12 Acknowledgments

- We sincerely appreciated the supporting by the Suzhou Science and Technology Plan 13
- Project (SKY2022151). We would also show sincere appreciation to the reviewers for 14
- 15 critical comments on this article.

17 **Ethics approval**

Not applicable. 18

20 **Data Availability Statement**

- 21 The data that support the findings of this study are available from the corresponding
- 22 author upon reasonable request.

Funding This work was supported by the Suzhou Science and Technology Plan Project (SKY2022151). **Authors' contribution:** Hui Li and Feng Li developed the concept of the study; Feng Li, You Zhang, Si-Liang Peng designed this study and carried out the data analysis; Feng Li wrote the manuscript with help from You Zhang, Si-Liang Peng, Meng-Chao Jin, Chi Geng, Venkatesh Ravi, Parikshit S. Sharma, and Pugazhendhi Vijayaraman; Hui Li, Venkatesh Ravi, Parikshit S. Sharma, and Pugazhendhi Vijayaraman provided critical reviews of the paper. All authors have read and approved the final manuscript. **Clinical trial registration:** https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023492551, identifier (CRD42023492551)

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

Abstract Background: Conduction system pacing (CSP) has been reported to improve clinical outcomes in comparison of right ventricular pacing (RVP). However, the performance between CSP and RVP on the risk of new-onset atrial fibrillation (AF) remains elusive. Methods: Four online databases were systematically searched up to December 1st 2023. Studies comprising the rate/risk of new-onset AF between CSP and RVP group were included. Subgroup analysis was performed to screen the potential determinants for the new-onset AF risk for CSP therapy. Moreover, the pooled risk of new-onset AF based on ventricular pacing burden (Vp) between CSP and RVP group were evaluated. **Results:** A total of five studies including 1,491 patients requiring pacing therapy were eligible. The pooled new-onset AF rates for CSP and RVP group were 0.09 and 0.26, respectively. Compared with RVP group, CSP group showed a lower pooled risk (risk ratio [RR] 0.38, P=0.000) and adjusted risk (hazard ratio [HR] 0.33, P=0.000) of new-onset AF. Meanwhile, a significant intervention-covariate interaction for the adjusted risk of new-onset AF between CSP and RVP group was identified with Vp < 20% and $Vp \ge 20\%$. **Conclusions:** Our study suggests that CSP is superior to reduce the new-onset atrial fibrillation risk compared with RVP. The $Vp \ge 20\%$ may be the key determinant on the lower risk of new-onset AF with CSP therapy.

Key words: Conduction system pacing; His bundle pacing; Left bundle branch area pacing; Right ventricular pacing; New-onset atrial fibrillation

22

1. Introduction 2 3 Right ventricular pacing (RVP), including right ventricular apex pacing and right ventricular septal pacing, has been widely utilized for patients with symptomatic 4 bradycardia owing to multiple advantages, including relatively easy implantation, 5 satisfying efficacy, and operation safety^[1, 2]. Whereas, concerns have arisen with the 6 7 increasing evidence on RVP. Accumulated studies suggest that RVP is significantly associated with the ventricular electromechanical dyssynchrony, ultimately causing to 8 increased atrial arrhythmias, heart failure, and mortality^[3, 4]. Therefore, establishment 9 10 of an alternative pacing strategy for decreasing the risk of new-onset AF after pacing 11 therapy is necessary. 12 Conduction system pacing (CSP), including His bundle pacing and left bundle branch pacing (LBBP), or left bundle branch area pacing (LBBaP), is a promising 13 physiological pacing strategy with the intriguing clinical outcomes, incluing reduction, 14 even reversal of the adverse clinical outcomes related to RVP^[5, 6]. Our recent 15 published meta-analysis on the effects of CSP in patients of heart failure indicated that 16 17 CSP showed a more effective performance on the heart failure patients than conventional pacing therapy, which further indicated that CSP is a superior pacing 18 strategy to achieve a better clinical prognosis^[7]. 19 20 New-onset atrial fibrillation (AF) is a concern with pacing therapy due to its risk 21 of progressing into persistent AF, increasing stroke/systolic embolism, left ventricular

dysfunction, as well as impaired quality of life. Accumulated evidence demonstrated

that RVP was significantly with the occurrence of new-onset AF. Whereas, evidence on the advantage of CSP versus RVP on the risk of new-onset AF remains elusive on account of limitation of small cohort of patients, lack of long-term follow-up, and a relatively high technical threshold with CSP. Therefore, we performed this registered study to explore if CSP is superior to reduce the new-onset atrial fibrillation risk compared with RVP.

2. Methods

2.1 Study design

- 4 This study was performed following the preferred reporting items for reviews and the
- 5 PRISMA guidelines (Supplementary PRISMA Checklist). The official protocol was
- 6 registered on the PROSPERO database (CRD42023492551).

2.2 Search strategy

Two reviewers (Feng Li and You Zhang) independently searched for four databases, including PubMed, Cochrane Library, Web of Science and Embase from the establishment of the online databases up to 1 December 2023. The searching keywords mainly included "conduction system pacing", "CSP", "His pacing", "Hisian area pacing", "His bundle pacing", "left bundle branch pacing", "LBBP", "left bundle branch area pacing", "LBBaP", "right ventricular pacing", "RVP", "right ventricular apex pacing", "right ventricular septal pacing", "atrial fibrillation", "new-onset atrial fibrillation", "new-onset AF" and "new-onset atrial high-rate episodes". The search strategy was presented in the **Supplementary Text 1**. Trials comprising the rate or risk of new-onset AF between CSP and RVP group were included. A manual search was also conducted to identify the potential publications. Moreover, the relevant corresponding authors were contacted to acquire the missing data related outcomes in their publications.

2.3 Study selection

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

Two reviewers (Feng Li and Si-Liang Peng) independently reviewed full texts for screening the eligible studies, respectively. The eligible study would be determined if inclusion criteria were met: (1) RCT and observational studies. (2) studies reporting the incidence rate of new-onset AF or (adjusted) risk ratio/hazard ratio of new-onset AF between CSP and RVP were included. (3) studies with the most data of multiple publications for the same study. Review articles, editorials, case reports, animal studies, and studies without original data were excluded. A third reviewer (Hui Li) discussed and resolved the potential disagreements on the eligibility. 2.4 Data extraction and quality assessment Two researchers (You Zhang and Meng-Chao Jin), respectively, acquired the data from all eligible studies. Any controversies were consulted and resolved by a third one (Hui Li). First, we documented the eligible study characteristics, including publication year, the first author, study design, subjects type, pacing type of CSP, the sample size in the CSP and RVP group, and follow-up. Then, the study demographic and clinical characteristics, as well as adjusted condounders were also recorded. A appraisal tool for observational studies was applied by two independent researchers (Si-Liang Peng and Meng-Chao Jin) to evaluate the quality of the eligible studies. In this study, the Newcastle-Ottawa Quality Assessment Scale (NOS), including three domains with nine points, was used. The study quality was divided

into low quality (the total score < 6) and moderate-to-high quality (the total score ≥ 6).

Any potential controversies were resolved by a third one (Hui Li).

1

2

3 2.5 Statistical analysis In this study, the pooled rates of the events (ratio of the number of events to patient 4 5 number) and 95% confidence interval (CI) were calculated for the new-onset AF with 6 CSP and RVP, respectively. The pooled risk ratio (RR) and corresponding 95%CI 7 were calculated for the risk of new-onset AF between CSP and RVP. The pooled hazard risk (HR) and corresponding 95%CI were calculated for the adjusted risk of 8 9 new-onset AF between CSP and RVP, as well as the adjusted risk of new-onset AF based on the Vp. The Stata 16.0 was used for analyses. Statistically significant was 10 defined as P < 0.05. 11 We utilized the I-squared (I²) and chi-squared test to quantify and evaluate the 12 statistical heterogeneity of studies. If the I² value was < 50% and/or $P \ge 0.05$ for the 13 chi-squared test, we defined that the between-study heterogeneity was substantial, and 14 15 a fixed-effect model would be performed. Otherwise, a random-effect model was performed. Sensitivity analysis was conducted by sequentially omitting one study at a 16 17 time to to evaluate the effect of a single study on the overall risk. Potential publication bias was also assessed using Egger's test. 18 Additionally, subgroup analysis was conducted to screen the sources of 19 heterogeneity, as well as the potential determinants for the new-onset AF between 20 21 CSP and RVP group. Based on the study characteristics, previously reported factors 22 and other potential factors, a total of five subgroup factors were screened, including

1 indication of implant (SND and AVB vs. AVB), pacing type of CSP (LBBaP vs. His

2 pacing), sample size (> 100 vs. \leq 100), follow-up time (> 24months vs. \leq 24months),

3 and new-onset AF type (Clinical AF vs. Subclinical AF). Important, we also evaluated

4 the adjusted new-onset AF risk between CSP and RVP group according to Vp

(including $Vp \ge 20\%$ vs. Vp < 20%, and $Vp \ge 40\%$ vs. Vp < 40%).

3. Results

5

6

7

8

10

11

12

13

14

16

17

18

19

20

21

3.1 Study selection and quality assessment

9 A total of five observational studies^[8-12] with 1,491 patients requiring pacing therapy

(672 and 819 patients in CSP and RVP group, respectively) were eligible. The

selection flowchart according to the PRISMA 2020 flow diagram

(http://prisma-statement.org/prismastatement/flowdiagram.aspx) was presented in

Figure 1. The study demographic and clinical characteristics, as well as adjusted

condounders of the eligible studies were showed in **Table1**.

All five eligible studies^[8-12] enrolled the patients requiring the pacemaker

implantation (PMI), in which the indication of implant with sinus node dysfunction

(SND) and atrioventricular block (AVB) was emphasized in three eligible studies [8, 10,

11], and that with only AVB was highlighted in two eligible studies [9, 12]. Two eligible

studies^[8, 10] reported LBBaP, and three^[9, 11, 12] reported His pacing. New-onset AF was

reported as clinical AF^[8, 10-12] and subclinical AF (also named atrial high-rate

episodes)^[9]. Three studies reported the Vp with the cutoff value of 20% (including Vp

 $\geq 20\%^{[8,10,11]}$ and Vp < 20% subgroup^[8,10,11]), and two studies reported with Vp with

the cutoff value of 40% (including $Vp \ge 40\%^{[8,11]}$ and Vp < 40% subgroup^[8]). Only 1 one study^[12] compared the effects of three different pacing sites (such as His pacing, 2 3 right ventricular apex, and right ventricular septal) on the new-onset AF, whereas the risk of new-onset AF between His pacing and right ventricular apecx pacing was 4 5 available for further analysis in this study. The mean follow-up time from the eligible studies ranged from 11.1 months to 58.5 months^[8-12]. All five observational studies 6 7 showed a moderate-to-high quality (**Supplementary Table 1**). 8 3.2 The pooled new-onset AF rates for CSP and RVP group 9 All eligible studies [8-12] reported the new-onset AF rate for CSP therapy and RVP 10 11 therapy, respectively. The pooled rates of new-onset AF with random-effect model were 0.09 (95% CI, 0.05-0.14; P = 0.00; $I^2 = 68.54\%$; Figure 2A) and 0.26 (95% CI, 12 0.18-0.36; P = 0.00; $I^2 = 86.93\%$; **Figure 2B**), respectively, for CSP group and RVP 13 group, with an interaction P value of 0.001. This result suggested that the rate of 14 15 new-onset AF in CSP group was significantly lower compared with the RVP group. Sensitivity analysis showed that no substantial change was identified in the 16 overall combined proportion, which ranged from 0.07 (95% CI, 0.05-0.09) to 0.10 17 (95% CI, 0.06-0.19) for CSP group, and 0.23 (95% CI, 0.15-0.34) to 0.29 (95% CI, 18 0.18-0.45) for RVP group. This result revealed that no single study dominated the 19 20 combined proportion and heterogeneity. 21 Subgroup analysis was performed and the results displayed in **Table 2** and **Table**

the new-onset AF rate for CSP therapy, only one significant

22

For

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

intervention-covariate interaction was identified in sample size subgroup, including > 100 (pooled rate 0.07; 95% CI, 0.05-0.09) and \leq 100 (pooled rate 0.18; 95% CI, 0.10-0.26) with P=0.001 for interaction. Meanwhile, for the new-onset AF rate for RVP therapy, two significant intervention-covariate interactions were identified in sample size subgroup, including > 100 (pooled rate 0.18; 95% CI, 0.15-0.21) and \leq 100 (pooled rate 0.42; 95% CI, 0.32-0.52) with P = 0.000 for interaction, as well as new-onset AF type subgroup, including clinical AF (pooled rate 0.23; 95% CI, 0.15-0.31) and subclinical AF (pooled rate 0.45; 95% CI, 0.31-0.59) with P=0.006 for interaction. 3.3 The risk of new-onset AF between CSP and RVP group The risk of new-onset AF was assessed between CSP and RVP group from two aspects, including the pooled risk and adjusted risk. A total of five studies [8-12], including 633 patients with CSP therapy and 787 with RVP therapy in our study, reported the risk of new-onset AF between CSP group and RVP group. Compared with RVP group, CSP group was significantly associated with a lower new-onset AF risk (RR, 0.38; 95% CI, 0.28-0.51; P = 0.000; $I^2 = 0.00\%$; Figure 3) via a fixed-effect model. We also performed sensitivity analysis for the pooled risk of new-onset AF and found that no significant change in the overall combined proportion, ranging from 0.35 (95% CI, 0.25-0.49) to 0.41 (95% CI, 0.30-0.57). This analysis revealed that the combined proportion and heterogeneity could not be dominated via a single study

(Supplementary Figure 1). Meanwhile, publication bias was not displayed with 1 Egger's test (P = 0.079). These results suggested that our result was robust. The 2 3 subgroup analysis for the pooled risk of new-onset AF was performed and the results 4 were consistent with the pooled risk (**Table 4**). 5 In addition, the adjusted risk of new-onset AF was reported by five eligible studies^[8-12]. Similarly, we found that compared with RVP group, CSP group was 6 7 significantly associated with a lower adjusted risk of new-onset AF (HR, 0.33; 95% CI. 0.24-0.44: P = 0.000; $I^2 = 0.00\%$; **Figure 4**) via a fixed-effect model. Sensitivity 8 9 analysis also indicated that that no significant change, ranging from 0.28 (95% CI, 10 0.20-0.40) to 0.35 (95% CI, 0.24-0.50), in the overall combined proportion. Publication bias using Egger's test (P = 0.768) was not displayed. The subgroup 11 12 analysis for the adjusted risk of new-onset AF showed the consistent results with the pooled adjusted risk (Figure 5). 13 14 15 3.4 The adjusted new-onset AF risk between CSP and RVP group based on Vp Three eligible studies [8, 10, 11] reported the adjusted risk of new-onset AF between CSP 16 17 and RVP group based on $Vp \ge 20\%$ and Vp < 20%. The pooled HRs for the adjusted new-onset AF risk between CSP and RVP group with Vp > 20% and Vp < 20% were 18 0.24 (95% CI, 0.16-0.37; P = 0.000) and 0.65 (95% CI, 0.35-1.21; P = 0.000),19 respectively. Importantly, a statistically significant intervention-covariate interaction 20 21 was identified in Vp subgroup, including $Vp \ge 20\%$ and Vp < 20% with P = 0.010 for

interaction (Figure 6).

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

Also, we evaluated the adjusted risk of new-onset AF between CSP and RVP group based on $Vp \ge 40\%$ and Vp < 40% with two eligible studies [8, 11]. We found that compared with RVP group, the adjusted new-onset AF risk of CSP group was significantly decreased in Vp > 40% subgroup (HR = 0.25; 95% CI, 0.14–0.42; P =0.000) and it was not in Vp < 40% subgroup (HR = 0.57; 95% CI, 0.26–1.27; P =0.168), respectively. Additionally, no statistically significant intervention-covariate interaction was displayed between Vp subgroups with P = 0.088 for interaction (Figure 7). 4. Discussion We comprehensively enrolled five observational studies with 1,491 patients requiring pacing therapy, including 672 patients in CSP group and 819 patients in RVP group. To our knowledge, our study may be the first registered meta-analysis to compare the risk of new-onset AF between CSP and RVP group. The main findings included: 1) The rate of new-onset AF in CSP group was significantly lower in comparison with the RVP group; 2) Compared with RVP group, CSP group showed a lower pooled risk, as well as the adjusted risk of new-onset AF; 3) A statistically significant intervention-covariate interaction with P = 0.010 was identified in Vp subgroup, including $Vp \ge 20\%$ and Vp < 20%. The schematic representation for this study is displayed in Figure 8. RVP, a well-established pacing strategy, has been widely utilized for patients requiring pacing therapy due to relatively easy implantation, satisfying efficacy, and

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

peocedural safety. Whereas, available evidence suggests that RVP is significantly related to the ventricular electricity and contraction dyssynchrony, promoting to the occurrence of pacing induced cardiomyopathy, ultimately leading to increased risk for atrial arrhythmias, heart failure, and mortality^[13]. New-onset AF, including clinical and subclinical AF, is of concern during pacing therapy, considering the risks of progressing into persistent atrial fibrillation, increasing rate of stroke/systolic embolism, left ventricular dysfunction, and impaired quality of life^[14]. Numerous studies had demonstrated that RVP was significantly associated with an increasing risk of new-onset AF, especially with the patients requring the high proportion of ventricular pacing [15-18]. Therefore, an alternative pacing strategy is needed to decrease the risk of new-onset AF after pacing therapy. CSP is an emerging and intriguing physiological pacing modality, facilitating decrease, or even reverse the adverse clinical outcomes associated with RVP. Our previuous study also revealed that CSP was more effective performance than conventional pacing therapy in heart failure patients, including shortened QRS duration, improved ventricular ejection fraction, improved NYHA class, higher response rate, as well as lower heart failure rehospitalization^[7]. Meanwhile, an increasing evidence indicated that CSP was statistically associated with a reduced risk of new-onset AF in comparison of RVP^[8, 10, 11]. In this study, our results also suggested that compared with RVP therapy, CSP therapy could significantly decrease the new-onset AF rate for patients requiring the pacing therapy, which might further increase evidence to highlight the superior perfomance on CSP.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

Several risk factors have been reported to be involved in pacing induced pacing induced cardiomyopathy. Lee *et al.*^[19] performed a retrospective study of 234 patients underwent a permanent pacemaker implantation with RVAP from 1982 to 2004, and found that older age at implantation was an idependent predictor for pacing induced heart failure (HR = 1.62; 95% CI, 1.22–2.16; P = 0.001). The latest meta-analysis performed by Somma et al. [20] with twenty-six studies including a total of 57,993 patients suggested that male gender, chronice kidney disease, previous myocardial infarction, native QRS duration, and paced QRS duration were identified to be the most important risk factors for pacing induced cardiomyopathy. Moreover, our previous studies also revealed that high-volume center (also meant a high sample size for a key technique) representing a relatively advanced operational team, was significantly associated with a better effacacy and comparable safety^[7, 21]. Whereas, very few studies have reported the potential risk factors for the potential pacing induced new-onset AF. In this report, consistent with the previous studies^[7, 21], we found that the sample size > 100 was considered as a key factor for reduction of the new-onset AF rate for CSP and RVP, respectively, in comparison of that less than 100. This results also provided an inspiration to our future research that the sample size with cutoff 100 might be appropriate and necessary to acquire the relatively stable and real-world rate, instead of the pseudo-high rate, of new-onset AF post pacing. Subclinical AF has been demonstrated to be associated with the risk of clinical AF^[22]. A recent meta-analysis with eleven studies conducted by Mahajan R et al. [23] showed that the risk of clinical AF was as high as 5.7 (95% CI, 4.00–8.00; P < 0.001) in

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

patients with subclinical AF. Our subgroup analysis for the subclinical AF rate with RVP therapy was significantly higher than clinical AF rate, whereas both rates were similar with CSP therapy. This result might partly explain the high new-onset AF rate in RVP therapy owing to the high incidence of subclinical AF. Our study also indicated that CSP group could significantly reduce the pooled risk, as well as adjusted risk of new-onset AF risk compared with RVP group. Additionally, subgroup analysis showed similar results. While His pacing has been demonstrated to be the feasibility and safety of intrinsic conduction system pacing, whereas it failed to widespread performed due to multiple concerns, such as unstable and elevated thresholds and relatively with follow-up. Excitingly, LBBaP or LBBP has been more widely adopted relatively low and stable pacing thresholds [24, 25]. Interestingly, our study showed that the rate and risk of new-onset AF between LBBaP subgroup and His pacing subgroup were similar, which indicated a consistent effect between both types of CSP. However, concerns must be paid for the higher pacing threshold with His pacing during long-term follow-up, potentially leading to excessive battery consumption and premature pacing lead revision. In addition, our study also suggested that follow-up did not affect the role of CSP in reducing the new-onset AF. Previous studies had demonstrated that individual with SND showed a high risk of new-onset AF on account of abnormal sinoatrial node function and increased automaticity of atrium^[26]. A two-community based cohort study including a total of 19,893 individuals with a follow-up of seventeen years revealed that SND could

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

significantly increase the risk of AF as high as 5.75 after adjustment of multiple cardiovascular diseases^[27]. A latest meta-analysis with thirty-five studies performed by Liu et al. [28] demonstrated that patients with SND showed a higher new-onset AF risk in comparation of those with AVB (RR, 3.45; 95% CI, 1.54-7.69; P = 0.003). Therefore, we made a reasonable speculation that the new-onset AF rate, theoretically, should be higher in eligible studies with the indication of SND and AVB, while that be lower in these with indication of AVB. Whereas, in our study the similar results between SND and AVB subgroup and AVB subgroup were shown in the analysis of new-onset AF rates of CSP therapy and RVP therapy, as well as the risk of new-onset AF between CSP and RVP group. This result seemed contradictory to previous studies and our speculations. The potential explanations for our result are as follow: The pacing therapy with timely restoration of heart rates with normal atrioventricular conduction might significantly interrupt the natural progression of the SND and AVB, ultimately leading to the occurrence of new-onset AF that mainly depended on pacing percentage or pacing modality. Vp was a key determinant in the new-onset AF risk between CSP and RVP group, with a positive linear relationship between the risk of AF and Vp^[15]. Importantly, screening an optimal Vp cutoff value for recommendation of CSP therapy to prevent new-onset AF or even pacing induced cardiomyopathy is of great interes to the pacing community. The 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay suggested that more physiologic ventricular activation (such as His pacing) should be

preferentially provided with the patients requiring $Vp > 40\%^{[29]}$. The lastest 1 2 HRS/APHRS/LAHRS guideline defined the substantial Vp of ≥ 20%-40% and 3 highlighted that patients who underwent pacemaker implantation and were expected to require substantial Vp may be considered for CSP to reduce pacing-induced 4 cardiomyopathy risk^[30]. Our study showed that CSP could significantly reduce the 5 6 new-onset AF risk in $Vp \ge 20\%$ subgroup, as well as $Vp \ge 40\%$ subgroup, compared 7 with RVP. Whereas, only one significant intervention-covariate interaction was 8 identified between $Vp \ge 20\%$ and Vp < 20% subgroup, rather than $Vp \ge 40\%$ and Vp9 < 40% subgroup. The potential explanation might be that some patients (e.g., Vp 20%-40%) could benefit from CSP compared with RVP in Vp < 40% subgroup, which 10 11 leading to a more overlap in 95%CI and no significant interaction between $Vp \ge 40\%$ 12 subgroup and Vp < 40% subgroup. More studies should be designed and performed to identify the minimal Vp cutoff value during 20%-40%, with that a significant 13 interaction could be achieved, thus providing strong evidence for the guideline with 14 15 optimal Vp cutoff value.

5. Limitations

16

17

18

19

20

21

22

There are several limitations in our study. First, all eligible studies in this analysis belonged to retrospective or observational studies, which has inherent limitations (such as inevitable confounding factors), thus leading to possiblely unreliable results^[31]. Whereas, the adjusted risk of new-onset AF was analyzed to minimize the effect of confounders as much as possible. Notably, the pooled risk and the adjusted

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

risk of new-onset AF from our eligible studies were similar, suggesting that our results were reliable. Our findings should be further assessed in further multicenter randomized trials with longer follow-up and larger sample size. Second, accumulated studies suggested that LBBP achieved left ventricular synchrony but induced right ventricular conduction delay^[32]. Bipolar LBBP was expected to improve the bi-ventricular electrical synchrony in comparison of unipolar LBBP, futher achieving more physiological conduction system activation^[33]. However, no data to date was reported on the risk of new-onset AF between bipolar and unipolar LBBP. Therefore, this might be a promising and novel perspective to provide related evidence for the optimal pacing therapy. Third, some potential biases derived from meta-analysis, might power our results. Considering that, sensitivity analysis and publication bias test both suggested our results were relatively robust. **6. Conclusions** Our study suggests that CSP is superior to reduce the new-onset atrial fibrillation risk compared with RVP. The $Vp \ge 20\%$ may be the key determinant of the lower risk of new-onset AF with CSP therapy. More multicenter randomized trials with longer follow-up and larger sample size should be conducted to further confirm our findings.

Figure legends

Figure 1.




Figure 1. The flowchart for selecting the eligible studies.

Figure 2.

1

2

3




Figure 2. Forest plot of the new-onset AF rates for CSP and RVP group. A. The

- pooled rates of new-onset AF for CSP group; B. The pooled rates of new-onset AF for 6
- RVP group. CSP: conduction system pacing; RVP: right ventricular pacing; AF: atrial 7

fibrillation.

Figure 3.

		CSP	RVP		Risk Ratio	%
Author	Year	n/N	n/N		(95% CI)	Weight
Zhu	2023	19/257	46/270		0.43 (0.26, 0.72)	29.73
Takahashi	2023	2/22	21/47€	•	0.20 (0.05, 0.79)	8.87
Ravi-1	2022	9/173	43/237 -	•	0.29 (0.14, 0.57)	24.04
Ravi-2	2020	15/72	31/76	-	0.51 (0.30, 0.86)	19.98
Pastore	2016	8/109	32/157	_	0.36 (0.17, 0.75)	17.38
Overall, MH		53/633	173/787	\Diamond	0.38 (0.28, 0.51)	100.00
$(l^2 = 0.0\%, p = 0.567)$	7)					
NOTE: Weights are from M	fantel-Haensz	el model				
			0.1	0.4	1	
			Favours CSF		o Favours RVP	

- Figure 3. Forest plot of the risk of new-onset AF between CSP and RVP group.
- Comparison of the rate of new-onset AF between CSP and RVP group. CSP:
- conduction system pacing; RVP: right ventricular pacing; AF: atrial fibrillation.

Figure 4.

Author	Year		HR (95% CI)	Weight %
Zhu	2023	-	0.28 (0.16, 0.50)	27.08
Takahashi	2023 ←	*	0.21 (0.04, 0.78)	4.11
Ravi-1	2022		0.33 (0.15, 0.67)	16.08
Ravi-2	2020		0.53 (0.28, 0.99)	22.72
Pastore	2016	-	0.28 (0.16, 0.48)	30.02
Overall, IV ($I^2 = 0$.	0%, p = 0.525)	\Diamond	0.33 (0.24, 0.44)	100.00
	0.05	0.5		
	Favo		Ratio Favours RVP)

- Figure 4. Forest plot of the adjusted risk of new-onset AF between CSP and RVP
- group. Comparison of the adjusted risk of new-onset AF between CSP and RVP group.
- CSP: conduction system pacing; RVP: right ventricular pacing; AF: atrial fibrillation.

Figure 5.

Subgroup factors	Study number	P value	P for interaction	HR (95% CI)
Indication of implant SND and AVB AVB	3 2	0.000 0.000	0.371	0.36 (0.25, 0.52) 0.27 (0.16, 0.45)
Pacing type LBBaP His pacing	2 3	0.000 0.000	0.560	0.30 (0.19, 0.47) 0.35 (0.24, 0.53)
Sample size >100 <=100	3 2	0.000 0.001	0.180	0.29 (0.20, 0.41) 0.46 (0.26, 0.82)
Follow-up >24 <=24	1 4	0.000 0.000	0.505	0.28 (0.16, 0.48) 0.35 (0.24, 0.50)
New-onset AF type Clinical AF Subclinical AF	4 1	0.000 0.022	0.550	0.33 (0.25, 0.45) 0.21 (0.05, 0.93)
			0.1 Favours CSP Hazard Ration	l 1 o Favours RVP

Figure 5. Forest plot of the adjusted risk of new-onset AF between CSP and RVP group. Subgroup analysis of the adjusted risk of new-onset AF between CSP and RVP group. CSP: conduction system pacing; RVP: right ventricular pacing; AF: atrial fibrillation.

Figure 6.




Figure 6. Forest plot of the adjusted risk of new-onset AF between CSP and RVP group based on Vp ≥ 20% subgroup and Vp < 20% subgroup. CSP: conduction system pacing; RVP: right ventricular pacing; AF: atrial fibrillation; Vp: ventricular pacing burden.

Figure 7.




Figure 7. Forest plot of the adjusted risk of new-onset AF between CSP and RVP group based on Vp ≥ 40% subgroup and Vp < 40% subgroup. CSP: conduction system pacing; RVP: right ventricular pacing; AF: atrial fibrillation; Vp: ventricular pacing burden.

Figure 8.

1

2

3

4

5

6

7

8

9

10

11

12

13





Figure 8. Schematic Representation. A. Pacing pattern diagram and related electrocardiogram for RVP; B. Pacing pattern diagram and related electrocardiogram for CSP; C: The histogram for the new-onset AF rates for CSP and RVP group; D. The new-onset AF risk ratio or hazard ratio between CSP and RVP. CSP: conduction system pacing; RVP: right ventricular pacing; HB: His bundle; RBB: right bundle branch; LBB: left bundle branch; AF: atrial fibrillation; SR: sinus rhythm; IVS: interventricular septum; RVAP: right ventricular apex pacing; RVSP: right ventricular

- septal pacing; LBBP: left bundle branch pacing; LBBaP: left bundle branch area
- pacing; Vp: ventricular pacing burden.

Supplementary Figure 1



- Supplementary Figure 1. The sensitivity analysis for the pooled risk of new-onset
- AF.

1 2 3 4 5 6 References 7 Inoue N, Ogane T, Hiramatsu T, et al. Relationship between left-axis deviation 8 [1] 9 and onset of cardiac adverse events in right ventricular pacing. J Electrocardiol. 2023. 80: 119-124. 10 Healey JS, Yee R, Tang A. Right ventricular apical pacing: a necessary evil. 11 [2] 12 Curr Opin Cardiol. 2007. 22(1): 33-8. [3] Huizar JF, Kaszala K, Tan A, et al. Abnormal cconduction-induced 13 ccardiomyopathy: JACC review topic of the week. J Am Coll Cardiol. 2023. 14 15 81(12): 1192-1200. Fletcher-Hall S. Pacemaker-induced cardiomyopathy. JAAPA. 2023. 36(9): 16 [4] 1-4. 17 Mao Y, Duchenne J, Yang Y, et al. Left bundle branch pacing better preserves 18 [5] ventricular mechanical synchrony than right ventricular pacing A two-center 19 study. Eur Heart J Cardiovasc Imaging. 2023. 20 21 [6] Keene D, Anselme F, Burri H, et al. Conduction system pacing, a European 22 survey: insights from clinical practice. Europace. 2023. 25(5).

- 1 [7] Zhang J, Li F, Zhang ZY, et al. Conduction system pacing is superior to
- 2 biventricular pacing in patients with heart failure: Insights from the pooled
- 3 clinical studies. Front Physiol. 2023. 14: 1125340.
- 4 [8] Zhu H, Li X, Wang Z, et al. New-onset atrial fibrillation following left bundle
- 5 branch area pacing vs. right ventricular pacing: a two-centre prospective
- 6 cohort study. Europace. 2023. 25(1): 121-129.
- 7 [9] Takahashi M, Kujiraoka H, Arai T, et al. New-onset atrial high-rate episodes
- 8 between his bundle pacing and conventional right ventricular septum pacing in
- 9 patients with atrioventricular conduction disturbance. J Interv Card
- Electrophysiol. 2023.
- 11 [10] Ravi V, Sharma PS, Patel NR, et al. New-onset atrial fibrillation in left bundle
- branch area pacing compared with right ventricular pacing. Circ Arrhythm
- 13 Electrophysiol. 2022. 15(4): e010710.
- 14 [11] Ravi V, Beer D, Pietrasik GM, et al. Development of new-onset or progressive
- atrial fibrillation in patients with permanent HIS bundle pacing versus right
- ventricular pacing: results vrom the RUSH HBP registry. J Am Heart Assoc.
- 17 2020. 9(22): e018478.
- 18 [12] Pastore G, Zanon F, Baracca E, et al. The risk of atrial fibrillation during right
- 19 ventricular pacing. Europace. 2016. 18(3): 353-8.
- 20 [13] Ponnusamy SS, Syed T, Vijayaraman P. Pacing induced cardiomyopathy:
- 21 recognition and management. Heart. 2023. 109(18): 1407-1415.
- 22 [14] Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS

guideline for the diagnosis and management of atrial fibrillation: A report of 1 the American College of Cardiology/American Heart Association Joint 2 3 Committee on clinical practice guidelines. Circulation. 2023. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of 4 [15] 5 ventricular pacing on heart failure and atrial fibrillation among patients with 6 normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003. 107(23): 2932-7. 7 [16] Sweeney MO, Bank AJ, Nsah E, et al. Minimizing ventricular pacing to 8 9 reduce atrial fibrillation in sinus-node disease. N Engl J Med. 2007. 357(10): 1000-8. 10 Khurshid S, Epstein AE, Verdino RJ, et al. Incidence and predictors of right 11 [17] 12 ventricular pacing-induced cardiomyopathy. Heart Rhythm. 2014. 11(9): 1619-25. 13 Veasey RA, Arya A, Silberbauer J, et al. The relationship between right 14 [18] 15 ventricular pacing and atrial fibrillation burden and disease progression in 16 patients with paroxysmal atrial fibrillation: the long-MinVPACE study. 17 Europace. 2011. 13(6): 815-20. Lee SA, Cha MJ, Cho Y, et al. Paced QRS duration and myocardial scar 18 [19] 19 amount: predictors of long-term outcome of right ventricular apical pacing. Heart Vessels. 2016. 31(7): 1131-9. 20 Somma V, Ha FJ, Palmer S, et al. Pacing-induced cardiomyopathy: A 21 [20] 22 systematic review and meta-analysis of definition, prevalence, risk factors, and

- 1 management. Heart Rhythm. 2023. 20(2): 282-290.
- 2 [21] Li F, Sun JY, Wu LD, et al. The long-term outcomes of ablation with vein of
- 3 Marshall ethanol infusion vs. ablation alone in patients with atrial fibrillation:
- 4 A meta-analysis. Front Cardiovasc Med. 2022. 9: 871654.
- 5 [22] Andrade JG, Deyell MW, Bennett R, et al. Assessment and management of
- 6 asymptomatic atrial fibrillation. Heart. 2023.
- 7 [23] Mahajan R, Perera T, Elliott AD, et al. Subclinical device-detected atrial
- 8 fibrillation and stroke risk: a systematic review and meta-analysis. Eur Heart J.
- 9 2018. 39(16): 1407-1415.
- 10 [24] Raymond-Paquin A, Verma A, Kolominsky J, et al. Left bundle branch area
- pacing in patients with atrioventricular conduction disease: A prospective
- multicenter study. Heart Rhythm. 2022. 19(9): 1484-1490.
- 13 [25] Kron J, Bernabei M, Kaiser D, et al. Real-world performance of conduction
- system pacing compared with traditional pacing. Circ Arrhythm
- 15 Electrophysiol. 2023. 16(7): 411-412.
- 16 [26] Manoj P, Kim JA, Kim S, et al. Sinus node dysfunction: current understanding
- and future directions. Am J Physiol Heart Circ Physiol. 2023. 324(3):
- 18 H259-H278.
- 19 [27] Alonso A, Jensen PN, Lopez FL, et al. Association of sick sinus syndrome
- with incident cardiovascular disease and mortality: the atherosclerosis risk in
- 21 Communities study and Cardiovascular Health Study. PLoS One. 2014. 9(10):
- e109662.

1	[28]	Liu Y, Zheng Y, Tse G, et al. Association between sick sinus syndrome and
2		atrial fibrillation: A systematic review and meta-analysis. Int J Cardiol. 2023.
3		381: 20-36.
4	[29]	Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS
5		guideline on the evaluation and management of patients with bradycardia and
6		cardiac conduction delay: executive summary: A report of the American
7		College of Cardiology/American Heart Association Task Force on clinical
8		practice guidelines, and the Heart Rhythm Society. Circulation. 2019. 140(8):
9		e333-e381.
10	[30]	Chung MK, Patton KK, Lau CP, et al. 2023 HRS/APHRS/LAHRS guideline
11		on cardiac physiologic pacing for the avoidance and mitigation of heart failure.
12		Heart Rhythm. 2023. 20(9): e17-e91.
13	[31]	Boyko EJ. Observational researchopportunities and limitations. J Diabetes
14		Complications. 2013. 27(6): 642-8.
15	[32]	Lu W, Lin J, Li Y, et al. Quantitative analysis reveals influencing factors to
16		facilitate successful anodal-ring capture in left bundle branch pacing.
17		Europace. 2023. 25(6).
18	[33]	Curila K, Jurak P, Prinzen F, et al. Bipolar anodal septal pacing with direct
19		LBB capture preserves physiological ventricular activation better than

unipolar left bundle branch pacing. Front Cardiovasc Med. 2023. 10: 1140988.

 Table 1 The baseline characteristics of eligible studies

First author (year)	Study design	Subject types	Pacing type	Indication for implant	Follow-up - days; m, mon	(d,	
I list author (year)	Study design	Subject types	of CSP	CSP group	CSP group RVP group		10115,
Zhu (2023)	Prospective observational cohort	All patients with bradycardia and indicated for dual-chamber pacemaker implantation per the current guideline		Sinus node dysfunction (25.1%), Atrioventricular block (74.9%)	•	11.1±7.5m	
Takahashi (2023)	Retrospective cohort	Consecutive patients who underwent dual-chamber pacemaker implantation (PMI) for atrioventricular conduction disturbance (AVCD) based on current guidelines and had RV leads placed in the His bundle region or the RV septum region were enrolled.	His pacing	Atrioventricular conduction disturbance	Atrioventricular conduction disturbance	569±211d	

	Datas an action	Permanent pacemaker implantation with RVP				
		and LBBaP. Patients with <6 months of		Sinus node dysfunction	Sinus node dysfunction	
Ravi-1 (2022)	Retrospective cohort	follow-up, left ventricular ejection fraction	LBBaP	(20.2%), Atrioventricular	(23.6%), Atrioventricular	600±278d
	conort	<=35%, and known history of AF at initial		block (79.8%) block (76.4%)		
		implant, were excluded.				
	Retrospective cohort	Detients underseine initial deal chember		Sinus node dysfunction	Sinus node dysfunction	
Ravi-2 (2020)		Patients undergoing initial dual-chamber	His pacing	(51.4%), Atrioventricular (59.2%), Atrioventricular 1.95±0.	1.95±0.9y	
		pacemaker implants		block (48.6%)	block (40.8%)	
Pastore (2016)	Retrospective cohort	Patients who underwent pacemaker implantation for complete/advanced AVB	His pacing	Complete/advanced AVB	Complete/advanced AVB	58.5±26.5m

Table 1 Continued

	Sample	e size	Age (years)		Gender (male,		Hypert	ension	Diabete	es (%)	LVEF (%)		LAD (mm)	
First author (year)	CSP group	RVP group	CSP group	RVP group	CSP group	RVP group	CSP group	RVP group	CSP group	RVP group	CSP group	RVP group	CSP group	RVP group
Zhu (2023)	257	270	63.60±13.50	66.90±11.50	46.30	48.15	55.25	60.74	15.17	22.22	62.80±4.90	63.10±5.40	36.90±5.60	37.50±5.90
Takahashi (2023)	22	47	79.00±8.00	78.00±8.00	36.36	55.32	68.18	72.34	31.82	25.53	68.50±3.60	66.70±5.00	39.40±6.70	36.50±6.30
Ravi-1 (2022)	173	237	73.60±14.18	73.92±13.06	50.29	51.48	84.39	82.28	36.42	30.80	60.07±7.77	59.70±6.28	NA	NA
Ravi-2 (2020)	72	76	72.33±11.58	75.71±10.19	54.17	50.00	83.33	81.58	34.72	32.89	60.20±8.30	61.24±7.58	NA	NA
Pastore (2016)	148	189	74.10±8.50	79.10±8.30	64.86	51.32	85.14	86.24	24.32	23.28	62.00±7.00	60.00±7.00	47.60±8.10	48.20±8.10

Table 1 Continued

First author (year)	Adjusted confounders	Endpoints definition	AF detection device
Zhu (2023)	Baseline variables considered to be clinically relevant or that showed a univariate relationship with the outcome (<i>P</i> value < 0.1) were entered into multivariate Cox regression models	New-onset AF was defined as device-detected AF episodes lasting at least 30 s on intracardiac electrogram or surface 12-lead ECG. Atrial high-frequency episodes (atrial rate >=190 bpm) detected by devices were manually checked to verify the incidence of AF, which might be silent.	Intracardiac electrogram
Takahashi (2023)	Multivariate analysis was performed on all variables, including covariables, that were statistically significant in the univariate analysis and were generally associated with the incidence of newonset AHRE	New-onset atrial high-rate episodes (AHRE), also named subclinical AF, was defined as an atrial high-rate episode that occurred 3 months after PMI and lasted for > 6 min at an atrial heart rate > 190 bpm	Intracardiac electrogram (Pacemaker's memory)
Ravi-1 (2022)	Multivariable analysis adjusted for confounders of congestive heart failure status and use of angiotensin-converting enzyme inhibitor/angiotensinreceptor-blocker drugs	The primary outcome was new-onset AF episode >=30 seconds detected on scheduled device follow-up performed in-person and remotely. The secondary outcome was new-onset AF episode >=6 minutes.	Intracardiac electrogram
Ravi-2 (2020)	Cox's proportional hazard model was used to estimate the hazard ratio of the first occurrence of new-onset AF and progression of AF according to different pacing site (HBP or RVP), adjusted for various potential confounders identified between left ventricular ejection fraction (LVEF), left atrial indexed volume, percentage of atrial and ventricular pacing, age, sex, diabetes mellitus, hypertension, coronary disease,	New-onset AF episode7: Device detection of a true AF episode (lasting >=30 seconds) on intracardiac electrogram. Atrial high-rate episodes (AHREs) from device recordings were manually reviewed to confirm true AF and rule out other causes of AHREs. AHRE episodes were defined as episodes with an atrial intracardiac electrogram rate >=190 bpm. AHRE episodes >=6 minutes were also evaluated	

	QRS morphology, bundle branch block, use of antiarrhythmic	
	drugs (propafenone, flecainide, dofetilide, sotalol,	
	dronedarone, and amiodarone)	
	Cox's proportional hazard model was used to estimate hazard	
	ratio of first occurrence of persistent or permanent AF for	
	different RV pacing site (RVA, RVS, and HA) adjusted for	
	various potential confounders selected by forward stepwise	Follow-up examinations were conducted at 6-month intervals to seek (i)
	method (Wald) between: LV volumes (EDV), LVEF, left	the first occurrence of persistent or permanent AF in patients without a
Pastore (2016)	atrium diameter, per cent of atrial and ventricular pacing, age,	prior AF history, and (ii) the first occurrence of progression to persistent Implanted device
	gender, diabetes, hypertension, coronary disease, QRS	or permanent AF in patients with previous AF event before PM
	morphology (BBB), use of anti-arrhythmic drugs	implantation.
	(propafenone, flecainide, and amiodarone), angiotensin	
	I-converting enzyme inhibitory (ACE I) or angiotensin II	
	receptor blocker (ARB), and previous AF event.	

Table 2 The subgroup analysis for the rate of new-onset AF for CSP group

Factors	Numbers of study	Pooled incidence	95% CI	I2 (%)	P value	P for interaction
Indication of implant						0.673
SND and AVB	3	0.10	0.04-0.18	-	0.000	
AVB	2	0.07	0.03-0.13	-	0.000	
Pacing type of CSP						0.161
LBBaP	2	0.06	0.04-0.09	-	0.000	
His pacing	3	0.12	0.04-0.23	-	0.000	
Sample size						0.001
> 100	3	0.07	0.05-0.09	-	0.000	
≤ 100	2	0.18	0.10-0.26	-	0.000	
New-onset AF type						0.827
Clinical AF	4	0.09	0.05-0.14	76.09	0.000	

Subclinical AF	1	0.09	0.03-0.28	-	0.030	
Follow-up						0.560
> 24	1	0.07	0.04-0.14	-	0.000	
≤ 24	4	0.09	0.04-0.16	76.30	0.000	

SND: sinus node dysfunction; AVB: atrioventricular block; CSP: conduction system pacing; LBBaP: left bundle branch area pacing; AF: atrial fibrillation

Table 3 The subgroup analysis for the rate of new-onset AF for RVP group

Factors	Numbers of study	Pooled incidence	95% CI	I2 (%)	P value	P for interaction
Indication of implant						0.788
SND and AVB	3	0.24	0.14-0.36	-	0.000	
AVB	2	0.25	0.20-0.32	-	0.000	
Sample size						0.000
> 100	3	0.18	0.15-0.21	-	0.000	
≤ 100	2	0.42	0.34-0.51	-	0.000	
New-onset AF type						0.006
Clinical AF	4	0.23	0.15-0.31	83.42	0.000	
Subclinical AF	1	0.45	0.31-0.59	-	0.030	
Follow-up						0.253
> 24	1	0.20	0.15-0.27	-	0.000	

4 0.28 0.17-0.41 90.15 0.000

SND: sinus node dysfunction; AVB: atrioventricular block; RVP: right ventricular pacing; AF: atrial fibrillation

Table 4 The subgroup analysis for the pooled risk of new-onset AF between CSP and RVP group

Factors	Numbers of study	Risk Ratio	95% CI	I2 (%)	P value	P for interaction
Indication of implant						0.447
SND and AVB	3	0.41	0.29-0.56	0.00	0.000	
AVB	2	0.31	0.16-0.59	0.00	0.000	
Pacing type of CSP						0.811
LBBaP	2	0.37	0.24-0.55	0.00	0.000	
His pacing	3	0.40	0.26-0.60	0.00	0.000	
Sample size						0.682
> 100	3	0.37	0.26-0.52	0.00	0.000	
≤ 100	2	0.42	0.25-0.68	39.30	0.001	
New-onset AF type						0.345
Clinical AF	4	0.40	0.30-0.54	0.00	0.000	

Subclinical AF	1	0.20	0.05-0.79	0.00	0.022	
Follow-up						0.870
> 24	1	0.36	0.17-0.75	0.00	0.006	
≤ 24	4	0.38	0.28-0.53	0.00	0.000	

SND: sinus node dysfunction; AVB: atrioventricular block; CSP: conduction system pacing; RVP: right ventricular pacing; LBBaP: left bundle branch area pacing; AF: atrial fibrillation